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Our previous study demonstrated that 6-(pyrrolidin-1-yl)-2-(3-methoxyphenyl)quinazolin-4-one (HMJ38) was a potent
anti-tubulin agent. Here, HMJ38 was used as a lead compound to develop more potent anti-cancer agents and to examine
the anti-cancer mechanisms.
EXPERIMENTAL APPROACH
Using computer-aided drug design, 2-aryl-6-substituted quinazolinones (MJ compounds) were designed and synthesized by
introducing substituents at C-2 and C-6 positions of HMJ38. The cytotoxicity of MJ compounds towards human cancer cells
was examined by Trypan blue exclusion assay. Microtubule distribution was visualized using TubulinTrackerTM Green reagent.
Protein expression of cell cycle regulators and JNK was assessed by Western blot analysis.
KEY RESULTS
Compounds MJ65–70 exhibited strong anti-proliferative effects towards melanoma M21, lung squamous carcinoma CH27,
lung non-small carcinoma H460, hepatoma Hep3B and oral cancer HSC-3 cells, with one compund MJ66 (6-(pyrrolidin-1-yl)-
2-(naphthalen-1-yl)quinazolin-4-one) highly active against M21 cells (IC50 about 0.033 μM). Treatment of CH27 or HSC-3 cells
with MJ65–70 resulted in significant mitotic arrest accompanied by increasing multiple asters of microtubules. JNK protein
expression was involved in the MJ65–70-induced CH27 and M21 cell death. Consistent with the cell cycle arrest at G2/M
phase, marked increases in cyclin B1 and Bcl-2 phosphorylation were also observed, after treatment with MJ65–70.
CONCLUSIONS AND IMPLICATION
MJ65–70 are dual-targeted, tubulin- and JNK-binding, anti-cancer agents and induce cancer cell death through up-regulation
of JNK and interfering in the dynamics of tubulin. Our work provides a new strategy and mechanism for developing
dual-targeted anti-cancer drugs, contributing to clinical anti-cancer drug discovery and application.
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Abbreviations
CADD, computer-aided drug design; PQZ, 2-phenyl-4-quinazolinones; RMSD, root mean square deviation; SAR,
structure–activity relationships
Introduction
Microtubules are polymers that are made up of consecutive
dimers of α- and β-tubulin protein and play a crucial role in
cell mitosis. In recent years, drugs that derange microtubule
dynamics have been investigated and commonly used as
chemotherapeutic agents for a variety of cancers (Burns et al.,
2009; Choi et al., 2011). Several clinically used anti-cancer
drugs, such as paclitaxel and vinblastine, bind to microtu-
bules, thereby altering normal microtubule dynamics, which
induces cells to arrest at the G2/M phase of the cell cycle and
ultimately leads to apoptosis of cancer cells (Manfredi et al.,
1982; Hadfield et al., 2003). Therefore, microtubules are a
proven target for the development of new anti-cancer drugs
because they are critical for mitotic spindle fibre formation
and the separation of chromosomes at mitosis. JNK, also
known as stress-activated protein kinase, is the member of
the MAPK family. The activation of JNK has been demon-
strated to be involved in apoptosis of cancer cells, induced by
tubulin-binding agents (Sánchez-Perez et al., 1998; Ma et al.,
2009). It has also been reported that the phosphorylation of
Bcl-2 on Ser70 is not proportional to the extent of apoptosis
(Furukawa et al., 2000), and Bcl-2 phosphorylation is only a
marker of M-phase events (Ling et al., 1998). Furthermore,
drugs affecting the integrity of microtubules could induce
Bc1-2 phosphorylation (Haldar et al., 1997). Therefore, JNK
should also be an important target for the development of
new anti-tubulin drugs.
Cancer is the leading cause of death worldwide. Anti-
tubulin drugs such as vinblastine (microtubule-destabilizing)
and paclitaxel (microtubule-stabilizing) have been developed
against a variety of cancers. However, development of drug
resistance limits the effectiveness of paclitaxel and vinblas-
tine (Gottesman et al., 2002; Doyle and Ross, 2003). There-
fore, many investigators concentrated their efforts on
understanding the mechanisms of drug resistance or identi-
fying novel and highly specific anti-cancer drugs (Kartalou
and Essigmann, 2001; Agarwal and Kaye, 2003). Furthermore,
multi-target anti-cancer drugs were proposed to provide a
new opportunity for treating paclitaxel- or vinblastine-
resistant tumour cells.
In our earlier studies, substituted 2-phenyl-4-
quinazolinones (PQZs) were identified as potent inhibitors of
tubulin polymerization (Hour et al., 2000; Yang et al., 2004).
We also concluded that the substituents at C-6 of PQZs were
important to their anti-cancer activities. Compounds with
electron-donating groups, such as methoxy group, N-alkyl
group or a heterocyclic ring, at 6-position of PQZs displayed
promising anti-cancer activities. Among them, 6-methoxy,
6-N,N-dimethyl, 6-(pyrrolidin-1-yl), 6-(piperidin-1-yl) and
6-(morpholin-1-yl) PQZs showed strong cytotoxicity with
low IC50 values against a panel of human tumour cell lines.
Notably, 6-(pyrrolidin-1-yl)-2-(3-methoxyphenyl)quinazolin-
4-one (HMJ38) was the most potent anti-tubulin agent. Based
on our previous study, the five substituents described earlier
were selected as building blocks in our further design of more
potent cytotoxic anti-tubulin agents.
Molecular docking techniques were also applied in this
study to supplement the efficient and effective design of new
analogues. Computer-aided drug design (CADD) system is a
powerful tool in drug design process. Molecular docking
methodology that predicts the best mode by which a given
compound will fit into a binding site of a macromolecular
target is of practical importance for the generation of the lead
compound or optimizing the lead compound in drug discov-
ery. Molecular docking also allows the rapid screening of
many chemical structures and thus the identification of
promising candidates for practical synthesis and further
experimental processing (Bajorath, 2002; Booth and Zemmel,
2004; Chen et al., 2006). As the parent compound, HMJ38
was docked initially with tubulin to explore its ligand–
protein binding mode and binding energy. Subsequently,
new 2-aryl-6-substituted quinazolinones (MJ series com-
pounds) were designed based on the docking results with
HMJ38. Finally, the designed compounds were synthesized
and evaluated for in vitro anti-tumour activity.
The major purpose of this study was to identify more
potent anti-cancer compounds and to examine the underly-
ing mechanisms. A better understanding of the cytotoxic
mechanisms involved would assist in the development of
potent derivatives with high therapeutic efficacy. In this
study, the expression of JNK protein and microtubule assem-
bly were found to be involved in the cytotoxicity and G2/M
cell cycle arrest in HSC-3 and CH27 cells, induced by
compounds MJ65–70. The results of docking simulations




The crystal structures of tubulin with paclitaxel (1jff) or vin-
blastine (1Z2b), respectively, and JNK protein (3e7o) recov-
ered from the RCSB Protein Data Bank (http://www.rcsb.org/
pdb) were used as the targets for molecular docking. The
docking calculations of the designed compounds with
tubulin and JNK were performed with LigandFit program
within the software package Discovery Studio 2.5 (Accelrys,
San Diego, CA, USA), which is an automated tool for ligand–
protein docking and scoring. The prepared protein protocol
was used to prepare 1z2b, 1jff and 3e7o protein structures
including the following actions: standardize atom names,
insert missing atoms in residues and remove alternate con-
formations, insert missing loop regions based on SEQRES
data, optimize short and medium size loop regions with
Looper Algorithm, minimize remaining loop regions, and
calculate pK and protonate structure.
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General procedure for synthesis of
2-aryl-6-substituted-4-quinazolinones
(compounds 17–31)
The intermediate benzamides (2, 4, 5–13) were known
compounds and their preparation has been published in a
previous study (Hour et al., 2000). Sodium hydrogen
sulfite (0.8 g, 7.5 mmol) was added to a solution of
5-methoxy-2-aminobenzamide (9) (1.2 g, 7.3 mmol) and
1-naphthaldehyde (14) (1.1 g, 7.3 mmol) in N,N-
dimethylacetamide (20 mL). The mixture was heated with
stirring at 150°C for 3 h and poured into ice water (200 mL).
The precipitate was collected, washed with water and dried in
vacuo. After purification by column chromatography (silica
gel; chloroform) and followed by recrystallization from EtOH,
6-methoxy-2-(naphthalen-1-yl)-4-quinazolinone (17) was
obtained (1.5 g, 70%) as pale yellow needles. The method
used to prepare 17 was also applied with the appropriate
substituted benzaldehyde and benzamide to afford 18–31.
Yields ranged from 60 to 70%.
Synthesis of 6-methoxy-2-(naphthalen-1-yl)
quinazolin-4-one (17, MJ70)
1.5 g from 5-methoxy-2-aminobenzamide (9) (1.2 g,




1.4 g from 5-methoxy-2-aminobenzamide (9) (1.2 g,
7.3 mmol) and indo-3-carboxaldehyde (15) (1.1 g,
7.3 mmol): brown crystals.
Synthesis of 6-methoxy-2-(benzo[b]thiophen-
3-yl)quinazolin-4-one (19, MJ79)
1.3 g from 5-methoxy-2-aminobenzamide (9) (1.2 g,
7.3 mmol) and thianaphthene-3-carboxaldehyde (16) (1.2 g,




1.5 g from 5-N,N-dimethyl-2-aminobenzamide (10) (1.3 g,




1.3 g from 5-N,N-dimethyl-2-aminobenzamide (10)
(1.3 g, 7.3 mmol) and indo-3-carboxaldehyde (15) (1.1 g,




1.5 g from 5-N,N-dimethyl-2-aminobenzamide (10) (1.3 g,
7.3 mmol) and thianaphthene-3-carboxaldehyde (16) (1.2 g,
7.3 mmol): pale yellow needles.
Synthesis of 6-(pyrrolidin-1-yl)-2-(naphthalen-
1-yl)quinazolin-4-one (23, MJ66)
1.6 g from 2-amino-5-(pyrrolidin-1-yl)benzamide (11) (1.5 g,




1.5 g from 2-amino-5-(pyrrolidin-1-yl)benzamide (11)
(1.5 g, 7.3 mmol) and indo-3-carboxaldehyde (15) (1.1 g,




1.5 g from 2-amino-5-(pyrrolidin-1-yl)benzamide (11) (1.5 g,
7.3 mmol) and thianaphthene-3-carboxaldehyde (16) (1.2 g,
7.3 mmol): brown powder.
Synthesis of 6-(piperidin-1-yl)-2-(naphthalen-
1-yl)quinazolin-4-one (26, MJ68)
1.6 g from 2-amino-5-(piperidin-1-yl)benzamide (12) (1.6 g,




1.6 g from 2-amino-5-(piperidin-1-yl)benzamide (12)
(1.6 g, 7.3 mmol) and indo-3-carboxaldehyde (15) (1.1 g,




1.6 g from 2-amino-5-(piperidin-1-yl)benzamide (12) (1.6 g,
7.3 mmol) and thianaphthene-3-carboxaldehyde (16) (1.2 g,




1.7 g from 2-amino-5-(morpholin-1-yl)benzamide (13) (1.6 g,




1.6 g from 2-amino-5-(morpholin-1-yl)benzamide (13)
(1.6 g, 7.3 mmol) and indo-3-carboxaldehyde (15) (1.1 g,




1.6 g from 2-amino-5-(morpholin-1-yl)benzamide (13) (1.6 g,
7.3 mmol) and thianaphthene-3-carboxaldehyde (16) (1.2 g,
7.3 mmol): brown crystals.
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Cell culture
The M21 cells were grown in monolayer culture in RPMI
medium 1640 (Invitrogen, Carlsbad, CA, USA) containing
10% FBS (HyClone Laboratories, Logan, UT, USA),
100 U·mL−1 penicillin and 100 μg·mL−1 streptomycin (Invit-
rogen) at 37°C in a humidified atmosphere comprising 95%
air and 5% CO2. CH27, H460 and Hep3B cells were cultured
in DMEM (Invitrogen) containing 5% FBS, 100 U·mL−1 peni-
cillin and 100 μg·mL−1 streptomycin and 2 mM glutamine
(Merck). HSC-3 cells were cultured in DMEM/F12 (1:1) with
L-glutamine and HEPES (HyClone) containing 5% FBS,
100 U·mL−1 penicillin and 100 μg·mL−1 streptomycin. When
cells were treated with 2-aryl-6-substituted quinazolinones,
culture medium containing 1% FBS was used.
Trypan blue exclusion assay
Cells were seeded at a density of 5 × 104 cells per well onto
12-well plates 48 h before being treated with drugs. The cells
were incubated with various concentrations of MJ series com-
pounds for 24 h. The control cultures were treated with 0.1%
DMSO. The number of viable cells was determined by stain-
ing the cell population with Trypan blue. After treatment,
cells were washed with PBS, trypsinized and the number of
unstained (viable) cells was counted.
Localization of microtubules
Cells grown on coverslips were treated with 0.1% DMSO or
with MJ65, 66, 67, 68, 69, 70 or 72 for 12 h. To detect
β-tubulin, cells were incubated for 30 min at 37°C with
250 nM TubulinTrackerTM Green reagent according to the
manufacturer’s instructions (Abcam, Cambridge, MA, USA).
The specimens were observed by fluorescence microscopy
(H600L, Nikon, Tokyo, Japan).
Cell cycle analysis
Cell cycle was determined as described previously (Wu et al.,
2011). After treatment, cells were stained with propidium
iodide (50 μg·mL−1) and analysed on a FACScan flow cytom-
eter (Becton Dickinson, San Jose, CA, USA). ModFit LT3.0
software (Verity Software House, Topsham, ME, USA) was
employed for cell cycle distribution analysis.
Protein preparation and Western
blot analysis
Protein preparation and Western blot analysis were performed
as described by Lee et al.,(2010). The protein concentrations
were estimated with the Bradford method. Equal amounts of
protein (50 μg) were separated by various indicated concen-
trations of SDS-PAGE, and the SDS-separated proteins were
electrotransferred to Immobilon-P Transfer Membranes (Mil-
lipore, Darmstadt, Germany). Membranes were probed with
antibodies to β-actin (1:5000), Bcl-2 (1:1000), Bcl-2(pS70)
(1:1000), Cdk1 (1:2500), cyclin B1 (1:500) and JNK (1:1000).
Secondary antibody consisted of a 1:20 000 dilution of HRP-
conjugated goat anti-mouse IgG (for β-actin, Bcl-2, cyclin B1,
Cdk1 and JNK) or HRP-conjugated goat anti-rabbit IgG [for
Bcl-2(pS70)]. The enhanced chemiluminescent detection
system (PerkinElmer Life and Analytical Sciences, Waltham,
MA, USA) was used for immunoblot protein detection.
Data analysis
Data are presented as means ±SEM and differences between
means assessed by Student’s t-test for paired data.
Materials
All of the solvents and reagents were obtained commercially
and used without further purification. TLC plates and silica
gel for column chromatography were purchased from Merck
(Darmstadt, Germany). Melting points were determined
with a Yanaco MP-500D (Kyoto, Japan) melting point appa-
ratus and are uncorrected. NMR spectra were obtained on a
Bruker Avance DPX-200 FT-NMR spectrometer (Billerica,
MA, USA) in DMSO-d6. MS spectra were measured with a
Finnigan/Thermo Quest MAT 95XL instrument (Bremen,
Germany).
Antipain, aprotinin, DTT, EGTA, leupeptin, pepstatin,
PMSF and Tris were purchased from Sigma (St. Louis, MO,
USA). Antibodies to various proteins were obtained from the
following sources: Bcl-2 and β-actin antibodies from Sigma;
cyclin B1, Cdk1 and JNK from BD Biosciences (San Jose, CA,
USA); Bcl-2(pS70) from (Abcam). HRP-conjugated goat anti-
mouse and anti-rabbit IgG were from Abcam Inc.
Results
Computer-aided drug design
In order to efficiently optimize HMJ38 and obtain prospective
potent candidates, the docking program LigandFit within the
software package Discovery Studio 2.5 was applied in our
design process. In our docking experiments, we found that
HMJ38 could dock into 1z2b using the vinblastine domain as
the binding site; moreover, there were more available space
and amino acid residues encompassed in the binding pocket,
which would allow us to introduce larger substituents into
the structure of HMJ38. Based on our preliminary suggestions
of structure–activity relationships (SAR) of PQZs, methoxy,
N,N-dimethyl, pyrrolidin-1-yl, piperidin-1-yl and morpholin-
1-yl substitutents were selected preferentially for incorpora-
tion at position 6 of PQZs. In addition, some aryl groups
larger than phenyl, such as naphthalen-1-yl, 1H-indol-3-yl
and benzo[b]thiophen-3-yl group, were introduced at the C-2
position of PQZs. The newly designed compounds were then
docked into the tubulin active site to explore their binding
positions and to calculate and rank their binding energies to
predict if the best binding poses are promising in actual
activity estimate. A virtual comparison of the new compound
MJ66 with the lead compound HMJ38, in tubulin was shown
in Figure 1A. We scored our models using several scoring
functions, LigScore, PLP, PMF and DockScore (Table 1-1). The
results showed that the designed 2-aryl-6-substituted quina-
zolinones (MJ series compounds) could bind adequately to
tubulin. For example, as shown in Figure 1B, MJ66 can bind
well to tubulin via hydrogen bonding and hydrophobic inter-
actions. A hydrogen bond is present between the quinazoline
ring (N3–H) of the ligand and Asp179. Complementary, van der
Waals interactions are also formed between the ligand and
Ser178, Asp179, Pro222, Thr223, Tyr224 and Ile332. These interactions
caused MJ66 to bind readily to tubulin. The other MJ series
compounds also bound well and in a similar mode. The
BJPDevelopment of novel dual-targeted anti-cancer agents
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Table 1-1
The docking results of MJ65-80 and HMJ38 with tubulin (1z2b)
Name LigScore1 LigScore2 (-)PLP1 (-)PLP2 Jain (-)PMF Dock_Score
MJ65 3.34 4.90 55.50 49.92 2.70 32.51 53.028
MJ66 3.21 5.13 63.69 55.36 1.66 16.46 56.452
MJ67 3.58 5.26 61.38 54.38 2.75 31.28 55.67
MJ68 3.20 5.16 69.37 60.84 1.64 21.00 57.04
MJ69 2.82 4.90 61.31 54.03 2.12 22.51 53.97
MJ70 3.21 4.83 63.33 52.82 1.09 19.4 49.31
MJ72 2.00 4.79 64.24 57.23 2.03 31.52 50.14
MJ73 1.61 4.48 54.57 47.51 0.85 16.00 53.39
MJ74 3.29 4.70 55.89 49.63 2.58 32.11 47.96
MJ75 3.30 4.72 50.17 44.98 2.76 30.15 52.10
MJ76 3.55 4.81 61.65 50.36 2.36 39.76 51.06
MJ77 3.34 4.97 58.94 53.4 2.71 33.11 56.54
MJ78 2.76 4.69 58.42 53.55 3.09 34.41 55.72
MJ79 2.54 4.34 46.62 40.91 1.56 21.28 52.01
MJ80 2.67 4.49 46.96 41.46 1.57 21.66 55.04
HMJ38 2.85 4.73 66.24 57.31 1.14 18.85 52.84
Table 1-2
The docking results of MJ65-80 and HMJ38 with JNK2 (3e7o)
Name LigScore1 LigScore2 (-)PLP1 (-)PLP2 Jain (-)PMF Dock_Score
MJ65 2.52 4.96 73.83 66.95 2.75 80.56 48.35
MJ66 3.36 5.21 69.95 64.42 2.24 61.93 46.09
MJ67 2.62 4.74 72.03 66.16 4.38 63.35 48.03
MJ68 1.89 4.98 81.62 78.49 4.70 88.18 49.30
MJ69 3.26 5.12 68.63 62.94 1.98 59.88 44.09
MJ70 3.22 5.09 68.89 63.57 2.42 57.78 43.16
MJ72 2.71 5.12 78.35 70.38 2.47 81.48 49.65
MJ73 1.88 5.17 79.09 74.58 3.73 74.92 50.86
MJ74 2.35 4.71 70.57 63.66 2.58 72.69 44.52
MJ75 2.58 4.94 75.59 68.10 2.06 74.48 44.90
MJ76 2.77 4.73 68.08 60.69 3.69 60.60 48.02
MJ77 2.84 4.91 68.95 61.98 3.87 58.70 49.62
MJ78 2.65 5.07 78.26 71.41 3.09 71.34 48.96
MJ79 3.04 5.15 67.72 61.38 0.87 54.99 45.47
MJ80 2.55 4.96 74.91 67.94 1.94 68.32 46.00
HMJ38 2.43 4.82 67.73 62.74 2.72 69.11 52.21
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vinblastine was re-docked into the tubulin–vinblastine
domain to generate an RMSD (root mean square deviation)
value of 1.9860 Å (Figure 1C).
Chemistry
All of the compounds were synthesized according to
Schemes 1–3. Structural elucidation of compounds was based
on careful inspections of spectroscopic data. The physical and




The synthesized 2-aryl-6-substituted quinazolinones (MJ65–
80) were assayed for cytotoxicity in vitro against five human
tumour cell lines, including M21 (malignant melanoma),
CH27 (lung squamous carcinoma), H460 (non-small cell lung
cancer), Hep3B (hepatoma) and HSC-3 (oral cancers). As
shown in Table 3, MJ65–70, 72 and 78 showed strong cyto-
toxic effects against the five tested cancer cell lines, with IC50
values ranging from 0.033 to 8.74 μM, while the remaining
compounds MJ73–77, 79 and 80 were inactive (IC50 > 10 μM).
MJ 66–70 displayed specifically anti-proliferative effects to
CH27, H460 and M21 cells, with IC50 values < 1 μM, except
for MJ69 with IC50 of 4.37 ± 0.33 μM in H460 cells. MJ66, 67,
69 and 70 displayed specifically anti-proliferative effects in
HSC-3 cells, with IC50 values < 1 μM. As to the selectivity of
these compounds for cancer cells, MJ78 showed specific selec-
tivity to HSC-3, and MJ72 showed selective cytotoxicity to
M21, H460 and Hep3B. On the whole, human hepatoma
Hep3B cells were not very sensitive to the new compounds,
compared with other cell lines.
Effects of MJ65–70 on microtubule polymerization of CH27 and
HSC-3 cells. We examined the effect of MJ65–70 on tubulin
distribution to determine if tubulins were targets in the
MJ65–70-induced cancer cell death. As shown in Figure 2,
mitotic spindles of cells blocked in anaphase by MJ65–70
were positioned in the vicinity of the spindle poles. Treat-
ment of HSC-3 or CH27 cells with MJ65–70 resulted in sig-
nificant mitotic arrest accompanied by increasing multiple
spindle poles of microtubules (Figure 2). The observed
changes were not the result of interaction of a Tubulin
Tracker Green reagent with polymerized tubulin as the
control cells did not show the inhibition of cell division. In
this study, MJ72 had no significant effect on the formation of




Molecular modelling. Virtual comparison of newly developed compound MJ66 with lead compound HMJ38 in tubulin (A) and JNK (B). MJ66
(yellow stick) docked well with tubulin (C) and JNK (D). The outputs of structural alignment show the superposition of vinblastine in
tubulin–vinblastine domain (E) and 35F in JNK-35F domain (F) with RMSD values of 1.9860 and 0.8931 Å respectively. The binding amino acids
are shown as lines and labelled. The carved surface representation of the pocket formed from MJ66 binding is shown as transparent blue-white-












a. (i) SOCl2, reflux  (ii) NH3 (g), dichloroethane, RT
Scheme 1
Synthesis of 5-methoxy-2-nitrobenzamide
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Effects of MJ65–70 on cell cycle distribution and the protein expres-
sion of cell cycle regulators, cyclin B1 and Cdk1, in CH27 and
M21 cells. As microtubules are essential for mitosis, we
therefore examined whether treatment with compounds
MJ65–70 induced G2/M phase arrest of cell cycle in CH27 and
M21 cells. Cell cycle analysis revealed S- and G2/M-phase
arrest after treatment of CH27 and M21 cells, with IC50 con-
centrations of MJ65–70 for 12 h. Significant S- and G2/M-
phase arrest was indicated by a decreasing proportion of cells
in the G0/G1-phase (Figure 3). It is interesting to note that
MJ72 had a slight effect on S- and G2/M-phase arrest after
treatment of CH27 or M21 cells with 10 or 8.1 μM, respec-
tively, for 12 h (Figure 3). These data indicated that MJ65–70
induced cancer cell death through the deranged spindle for-
mation and followed by mitotic arrest. To further evaluate the
involvement of specific regulators of cell cycle such as cyclin
B1 and Cdk1 in the S- and G2/M-phase arrest induced by
MJ65–70, the protein levels of cyclin B1 and Cdk1 were
analysed by Western blot analysis in CH27 and M21 cells. As
shown in Figure 4, the levels of cyclin B1 protein were con-
sistently increased in MJ65–70-treated CH27 and M21 cells.
However, there was no consistent Cdk1 protein expression in
CH27 and M21 cells after MJ65–70 treatment. MJ65–70
induced no significant changes in the protein amounts of
Cdk1 in CH27 cells (Figure 4). Treatment of M21 cells with
MJ65–67 caused a slight increase in Cdk1 protein levels
(Figure 4). However, expression of Cdk1 was decreased in
MJ72-treated CH27 and M21 cells (Figure 4).
Effects of MJ65–70 on JNK protein levels and Bcl-2 phosphoryla-
tion of CH27 and M21 cells. The result in Figure 4 shows
significant increase in the protein levels of JNK2 after treat-
ment with MJ65–70. Western blot analysis of the protein
expression of Bcl-2 exhibits two bands in this study. The
upper and lower bands correspond to phosphorylated and
non-phosphorylated Bcl-2 respectively. In this study, expo-
sure of CH27 and M21 cells to MJ65–70 resulted in a signifi-
cant increase in phosphorylated Bcl-2 protein level (Figure 4).
We also demonstrated that MJ65–70 induced Bcl-2 phospho-
rylation at Ser70 in CH27 and M21 cells (Figure 4). Based on
the above data, this study demonstrated that Bcl-2 phospho-
rylation, a marker of M-phase events, was induced after treat-















a. (i) SOCl2, reflux  (ii) NH3 (g), dichloroethane, RT
b. dimethylamine (or pyrrolidine, piperidine, morpholine), DMF, 110 oC
Scheme 2


























a. H2, Pd/C, methanol





2, 9, 17-19       R6 = OCH3
5, 10, 20-22     R6 =
6, 11, 23-25     R6 =
7, 12, 26-28     R6 =
8, 13, 29-31     R6 =
14, 17, 20, 23, 26, 29     R2 =
15, 18, 21, 24, 27, 30     R2 =
16, 19, 22, 25, 28, 31     R2 =
Scheme 3
Synthesis of 2-aryl-6-substituted quinazolinones
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Table 2
Physical and spectroscopic data of compounds 17–31
Compounds
Yield
(%) Mp (°C) Formula
HRMS-EI, m/z
(calcd.) 1H NMR (DMSO-d6)δ
17 (MJ70) 70 174–175 C19H14N2O2 302.1057
(302.1055)
3.87 (3H, s, OCH3), 7.22–7.34 (2H, m, 2 × ArH), 7.53–7.72 (5H,
m, 5 × ArH), 7.95–8.22 (3H, m, 3 × ArH), 12.62 (1H, br s, NH)
18 (MJ74) 68 311–312 C17H13N3O2 291.1001
(291.1008)
3.84 (3H, s, OCH3), 7.15–7.19 (2H, m, 2 × ArH), 7.35–7.49 (3H,
m, 3 × ArH), 7.63–7.68 (1H, m, 1 × ArH), 8.45 (1H, s,
1 × ArH), 8.46–8.63 (1H, m, 1 × ArH), 11.76 (1H, s, NH),
12.11 (1H, br s, NH)
19 (MJ79) 60 289–290 C17H12N2O2S 308.0628
(308.0619)
3.89 (3H, s, OCH3), 7.43–7.57 (4H, m, 4 × ArH), 7.76–7.80 (1H,
m, 1 × ArH), 8.07–8.11 (1H, m, 1 × ArH), 8.73 (1H, s,
1 × ArH), 8.98–9.01 (1H, m, 1 × ArH), 12.49 (1H, br s, NH)
20 (MJ69) 65 254–255 C20H17N3O 315.1367
(315.1372)
2.99 [6H, s, N(CH3)2], 7.22–7.34 (2H, m, 2 × ArH), 7.51–7.72
(5H, m, 5 × ArH), 7.96–8.23 (3H, m, 3 × ArH), 12.39 (1H, br
s, NH)
21 (MJ75) 60 >300 C18H16N4O 304.1316
(304.1324)
2.99 [6H, s, N(CH3)2], 7.17–7.34 (4H, m, 4 × ArH), 7.43–7.47
(1H, m, 1 × ArH), 7.58–7.63 (1H, m, 1 × ArH), 8.44 (1H, s,
1 × ArH), 8.65–8.69 (1H, m, 1 × ArH), 11.71 (1H, s, NH),
11.92 (1H, br s, NH)
22 (MJ80) 62 >300 C18H15N3OS 321.0941
(321.0936)
2.99 [6H, s, N(CH3)2], 7.20–7.67 (5H, m, 5 × ArH), 8.02–8.05
(1H, m, 1 × ArH), 8.63 (1H, s, 1 × ArH), 8.97–9.01 (1H, m,
1 × ArH), 12.21 (1H, br s, NH)
23 (MJ66) 65 276–277 C22H19N3O 341.1523
(341.1528)
1.99 (4H, m, CH2CH2NCH2CH2), 3.27 (4H, m, CH2NCH2),
7.10–7.21 (2H, m, 2 × ArH), 7.56–7.76 (5H, m, 5 × ArH),
8.01–8.21 (3H, m, 3 × ArH), 12.34 (1H, br s, NH)
24 (MJ65) 61 298 C20H18N4O 330.1488
(330.1481)
1.94 (4H, m, CH2CH2NCH2CH2), 3.28 (4H, m, CH2NCH2),
6.97–7.20 (4H, m, 4 × ArH), 7.39–7.43 (1H, m, 1 × ArH),
7.53–7.58 (1H, m, 1 × ArH), 8.38 (1H, s, 1 × ArH), 8.61–8.65
(1H, m, 1 × ArH), 11.68 (1H, s, NH), 11.88 (1H, br s, NH)
25 (MJ78) 60 >300 C20H17N3OS 347.1090
(347.1092)
1.97 (4H, m, CH2CH2NCH2CH2), 3.47 (4H, m, CH2NCH2),
7.43–7.57 (4H, m, 4 × ArH), 7.76–7.80 (1H, m, 1 × ArH),
8.07–8.11 (1H, m, 1 × ArH), 8.73 (1H, s, 1 × ArH), 8.98–9.02
(1H, m, 1 × ArH), 12.51 (1H, br s, NH)
26 (MJ68) 65 233–235 C23H21N3O 355.1680
(355.1685)
1.57–1.62 [6H, m, (CH2)2CH2NCH2CH2], 3.26–3.31 (4H, m,
CH2NCH2), 7.48–7.65 (6H, m, 6 × ArH), 7.72–7.76 (1H, m,
1 × ArH), 8.00–8.13 (3H, m, 3 × ArH), 12.43 (1H, br s, NH)
27 (MJ72) 64 >300 C21H20N4O 344.1638
(344.1637)
1.59–1.62 [6H, m, (CH2)2CH2NCH2CH2], 3.20–3.24 (4H, m,
CH2NCH2), 7.18–7.21 (2H, m, 2 × ArH), 7.41–7.48 (3H, m,
3 × ArH), 7.50–7.62 (1H, m, 1 × ArH), 8.46 (1H, s, 1 × ArH),
8.65–8.69 (1H, m, 1 × ArH), 11.73 (1H, s, NH), 11.96 (1H, br
s, NH)
28 (MJ73) 60 >300 C21H19N3OS 361.1240
(361.1249)
1.57–1.59 [6H, m, (CH2)2CH2NCH2CH2], 3.22–3.25 (4H, m,
CH2NCH2), 7.42–7.54 (4H, m, 4 × ArH), 7.63–7.67 (1H, m,
1 × ArH), 8.03–8.07 (1H, m, 1 × ArH), 8.66 (1H, s, 1 × ArH),
8.97–9.00 (1H, m, 1 × ArH), 12.30 (1H, br s, NH)
29 (MJ67) 64 291–293 C22H19N3O2 357.1470
(357.1477)
3.22 (4H, t, J = 4.7 Hz, CH2NCH2), 3.77 (4H, t, J = 4.7 Hz,
CH2OCH2), 7.51–7.66 (6H, m, 6 × ArH), 7.73–7.76 (1H, m,
1 × ArH), 8.00–8.11 (3H, m, 3 × ArH), 12.48 (1H, br s, NH)
30 (MJ76) 65 >300 C20H18N4O2 346.1434
(346.1430)
2.97 (4H, t, J = 4.7 Hz, CH2NCH2), 3.74 (4H, t, J = 4.7 Hz,
CH2OCH2), 7.12–7.22 (2H, m, 2 × ArH), 7.41–7.63 (4H, m,
4 × ArH), 8.43 (1H, s, 1 × ArH), 8.60–8.64 (1H, m, 1 × ArH),
11.76 (1H, s, NH), 12.01 (1H, br s, NH)
31 (MJ77) 60 >300 C20H17N3O2S 363.1034
(363.1041)
2.47 (4H, t, J = 4.7 Hz, CH2NCH2), 3.75 (4H, t, J = 4.7 Hz,
CH2OCH2), 7.44–7.59 (4H, m, 4 × ArH), 7.67–7.72 (1H, m,
1 × ArH), 8.03–8.07 (1H, m, 1 × ArH), 8.67 (1H, s, 1 × ArH),
8.96–9.00 (1H, m, 1 × ArH), 12.31 (1H, br s, NH)
HRMS-EI, high-resolution electron impact mass spectra; Mp, melting point.
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Docking simulation of MJ65–70 with JNK protein. Because JNK
was overexpressed by MJ65–70 (see Western blots; Figure 4),
we performed a docking simulation of these compounds with
JNK2 protein and found them to bind adequately with JNK2.
The virtual comparison of MJ66 with lead compound HMJ38
in JNK2 was shown in Figure 1D. The scoring function values
are listed in Table 1-2. MJ66 was taken as an example to
illustrate the interactions between ligand and binding site. As
shown in Figure 1E, the interaction between MJ66 and 3e7o
involved the van der Waals interactions of the quinazoline
ring with Val40, Ala53, Met108 and Leu168;the 6-(piperidin-1-yl)
group with Ile32; and the 2-(naphthalene-1-yl) group with
Lys55, Ile86, Met108, Leu168 and Asp169. These interactions caused
MJ66 to bind readily to JNK2. The 35F, co-crystal in the 3e7o,
was re-docked into the JNK-35F domain to generate an RMSD
value of 0.8931 Å (Figure 1F).
Discussion
In this study, HMJ38 was used as a lead structure to develop
novel and potent anti-tubulin compounds. We optimized
the structure of HMJ38 based on the results of the previous
SAR study and complementary molecular docking simula-
tions. In the process of docking simulation with tubulin, we
found that there is more available space in the ligand-
binding region encompassing available amino acid residues.
Therefore, we extended the structural skeleton through
introduction of substituents at the C-2 and C-6 positions.
The results of the docking simulations indicated that our
designed MJ series bind to tubulin mainly at the vinblastine
site, but not the colchicine or paclitaxel site. Therefore,
the optimized 2-aryl-6-substituted quinazolinones, like vin-
blastine, were supposed to be tubulin-binding agents via
inhibiting tubulin polymerization. These findings are con-
sistent with the pharmacological results in our previous
study, in which the interference in the dynamics of tubulin
and cell division of MJ69 is similar to that in vinblastine-
treated cells, but not paclitaxel-treated cells (Hour et al.,
2013).
The novel optimized 2-aryl-6-substituted quinazolinones
were then synthesized and demonstrated as anti-proliferative
agents towards M21, CH27, H460, Hep3B and HSC-3
cells. SAR studies indicated that compounds bearing 2-
(naphthalen-1-yl) groups (MJ66–70) exhibited strong cyto-
toxic activity regardless of which one of the five functional
groups substituted at their position 6. As for compounds
bearing 2-(1H-indol-3-yl) groups, only those substituted with
6-(pyrrolidin-1-yl) or 6-(piperidin-1-yl) (MJ65 and 72) were
active; however, their activity decreased significantly. All the
compounds bearing 2-(benzo[b]thiophen-3-yl) groups (MJ73,
77–80) were inactive in spite of which functional groups
substituted at their 6-positions, except for MJ78, which was
moderately active against HSC-3 cells. The selectivity of
MJ78 against HSC-3 cells will be investigated further in our
laboratory.
Table 3
In vitro cytotoxicity of 2-aryl-6-substituted quinazolinones
Compounds
IC50 (μM)
M21 CH27 H460 Hep3B HSC-3
17 (MJ70) 0.09 ± 0.006 0.09 ± 0.004 0.07 ± 0.02 1.94 ± 0.46 0.15 ± 0.03
18 (MJ74) >10 >10 >10 >10 >10
19 (MJ79) >10 >10 >10 >10 >10
20 (MJ69) 0.63 ± 0.042 0.43 ± 0.03 4.37 ± 0.33 8.74 ± 0.63 0.20 ± 0.03
21 (MJ75) >10 >10 >10 >10 >10
22 (MJ80) >10 >10 >10 >10 >10
23 (MJ66) 0.03 ± 0.005 0.05 ± 0.01 0.08 ± 0.01 1.35 ± 0.12 0.04 ± 0.003
24 (MJ65) 7.94 ± 0.66 8.14 ± 0.53 8.89 ± 0.45 7.50 ± 0.55 2.01 ± 0.37
25 (MJ78) >10 >10 >10 >10 4.97 ± 0.82
26 (MJ68) 0.44 ± 0.02 0.38 ± 0.01 0.38 ± 0.04 7.46 ± 0.90 1.65 ± 0.45
27 (MJ72) 8.1 ± 0.57 >10 6.86 ± 0.67 6.86 ± 0.81 >10
28 (MJ73) >10 >10 >10 >10 >10
29 (MJ67) 0.49 ± 0.05 0.78 ± 0.07 0.44 ± 0.04 1.11 ± 0.14 0.63 ± 0.06
30 (MJ76) >10 >10 >10 >10 >10
31 (MJ77) >10 >10 >10 >10 >10
HMJ38 3.44 ± 0.39 >10 >10 >10 2.69 ± 0.38
Cell viability was determined by Trypan blue exclusion assay. The IC50 values of 2-aryl-6-substituted quinazolinones were determined from
dose–response curves. All results are expressed as the mean percentage of control ± SD of triplicate determinations from three independent
experiments.
CH27, human lung squamous carcinoma; H460, human lung non-small carcinoma cells; Hep3B, human hepatoma; HSC-3, human oral
cancer cells; M21, human malignant melanoma.
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Overall, we concluded that 2-(naphthalen-1-yl) group is
the most important substituent contributing to their cytotox-
icity in this class of compounds, and compounds simultane-
ously substituted with 6-(pyrrolidin-1-yl) group led to the
most effective anti-cancer activity. MJ66 bearing both
2-(naphthalen-1-yl) and 6-(pyrrolidin-1-yl) moieties showed
the highest activity, with IC50 values of 0.03, 0.05, 0.08, 1.35
and 0.04 μM against M21, CH27, H460, Hep3B and HSC-3
cells respectively. MJ70 bearing both 2-(naphthalen-1-yl) and
6-methoxyl moieties showed slightly decreased activity, with
IC50 values of 0.09, 0.09, 0.07, 1.94 and 0.15 μM against M21,
CH27, H460, Hep3B and HSC-3 cells respectively. The cyto-
toxic activity of HMJ38 was also assayed in this study and
exhibited IC50 values of 3.44 and 2.69 μM against M21 and
HSC-3 cells respectively (Table 3). From the above findings,
MJ66–70 appear to be more potent anti-proliferative agents
than the lead compound HMJ38.
The aberrant expression of microtubules was associated
with cancer cell death induced by compounds MJ65-70.
Therefore, the anti-cancer mechanisms of these compounds
involved interactions with the formation of microtubules,
leading to the failure to the progression of cell cycle in CH27
and M21 cells. These results are consistent with previous
observations in which interference with the dynamics of
tubulin, by compounds such as taxanes and Vinca alkaloids,
and cell division have been proven to arrest cells at the G2/M
phase of the cell cycle, ultimately leading to apoptosis
(Roninson et al., 2001; Castedo et al., 2004). As our findings
suggest that MJ65–70 are anti-microtubule agents, the
mitotic arrest of cell cycle may result from their anti-
microtubule effects in cancer cells. Exposure of CH27 or M21
cells to MJ65–70 resulted in a significant increase in Bcl-2
phosphorylation in this study. This result appears to be con-
sistent with earlier findings that drugs affecting the integrity
of microtubules can induce Bc1-2 phosphorylation, which is
only a marker of M-phase events (Haldar et al., 1997; Ling
et al., 1998).
Because MJ65–70 induced the mitotic arrest of cells that
preceded cell death, the cell cycle regulators, in particular the
expression of cyclin B1 and Cdk1, were examined. In this
study, MJ65–70 induced a marked increase in the protein
level of cyclin B1 in M21 and CH27 cells. There is evidence
that cyclin B1 must be destroyed by the anaphase-promoting
complex to allow mitosis to proceed at the end of metaphase
(Peters, 2002). Based on the above data, mitotic arrest
induced by MJ65–70 may be associated with the accumula-
Figure 2
MJ65–70 induced changes in microtubule formation of CH27 and HSC-3 cells. Cells were incubated with 0.1% DMSO or IC50 concentrations of
MJ65–70 for 12 h. The concentration of MJ72 used in CH27 and HSC-3 is 10 μM. After treatment, cells were incubated for 30 min with 250 nM
Tubulin Tracker Green reagent. The specimens were observed by fluorescence microscopy. All results are representative of three independent
experiments.
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tion of cyclin B1, which is not destroyed at the end of meta-
phase. In this study, we also demonstrated that treatment of
cells with MJ65–70 resulted in many mitotic cells with
multipolar spindles and cell cycle arrest at G2/M phase.
In addition, several reports suggested that activation of
JNK may be a common mechanism for tubulin-binding agents
(Sánchez-Perez et al., 1998; Ma et al., 2009). In this study, we
also demonstrated that MJ65–70 significantly increased the
protein levels of JNK2. Therefore, JNK2 was selected as
another docking target in the hope of discovering a potent
dual-targeted anti-cancer agent. From the results of our ligand
docking experiments, MJ65–70 were well-matched with the
JNK molecule and should thus be promising JNK-binding
agents. Although the crystal structure of JNK1 was used as the
docking target in the docking experiments, we found that MJ
compounds bound more readily to JNK2 than to JNK1 (data
Figure 3
MJ65–70 induced cell cycle arrest of CH27 and M21 cells. Cells were treated with 0.1% DMSO or IC50 doses of MJ65–70 for 12 h. The
concentrations of MJ72 used in CH27 and M21 are 10.0 and 8.1 μM respectively. After treatment, cells were stained with propidium iodide and
analysed by flow cytometry. Results are representative of three independent experiments.
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not shown). The docking results were compatible with those
from the Western blot analysis. In our previous study, MJ69-
induced cell death was attenuated by the JNK inhibitor
SP600125 (3 or 10 μM), not by the inhibitors of ERK or p38.
Inhibition of JNK also abolished the MJ69-induced increase in
the phosphorylation of Bcl-2 (Hour et al., 2013). Therefore, we
suggested that the MJ compounds may be targetting JNK. In
the present study, we unexpectedly showed that MJ65–70
bound to both tubulin and JNK, and induced microtubule
disruption and cell cycle arrest at G2/M phase, leading to
cancer cell death with the phosphorylation of Bcl-2.1
In summary, CADD techniques were used to develop new
compounds and the LigScore2 was the better scoring func-
tion, which was in good agreement with our experimental
results in this study (higher scores indicate better ligand-
binding affinities). The MJ65–70 compounds were dual-
targeted, tubulin- and JNK-binding, anti-cancer agents and
induced cancer cell death through interfering in the dynam-
ics of tubulin and JNK regulation. Treatment of CH27 or
HSC-3 cells with MJ65–70 resulted in significant mitotic
arrest accompanied by increasing multiple asters of microtu-
bules. In accordance with the cell cycle arrest at G2/M phase
induced by the MJ65–70 compounds, we also found a marked
increase in Bcl-2 phosphorylation. Our work provides a new
strategy and mechanism for developing dual-targeted anti-
cancer drugs and may contribute to clinical anti-cancer drug
discovery and application.
Acknowledgements
This work was supported by research grant from the National
Science Council of the Republic of China (NSC 99–2320-B-
039-013-MY3; NSC97-2320-B-039-024).
Conflict of interest
The authors state no conflict of interest.
References
Agarwal R, Kaye SB (2003). Ovarian cancer: strategies for
overcoming resistance to chemotherapy. Nat Rev Cancer 3:
502–516.
Bajorath J (2002). Integration of virtual and high-throughput
screening. Nat Rev Drug Discov 1: 882–894.
Booth B, Zemmel R (2004). Prospects for productivity. Nat Rev
Drug Discov 3: 451–456.
Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, Bukczynska PE
et al. (2009). CYT997: a novel orally active tubulin polymerization
inhibitor with potent cytotoxic and vascular disrupting activity in
vitro and in vivo. Mol Cancer Ther 8: 3036–3045.
Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R,
Kroemer G (2004). Cell death by mitotic catastrophe: a molecular
definition. Oncogene 23: 2825–2837.
Chen H, Lyne PD, Giordanetto F, Lovell T, Li J (2006). On
evaluating molecular-docking methods for pose prediction and
enrichment factors. J Chem Inf Model 46: 401–415.
Choi HJ, Fukui M, Zhu BT (2011). Role of cyclin B1/Cdc2
up-regulation in the development of mitotic prometaphase arrest in
human breast cancer cells treated with nocodazole. PLoS ONE 6:
e24312.
Doyle LA, Ross DD (2003). Multidrug resistance mediated by the
breast cancer resistance protein BCRP (ABCG2). Oncogene 22:
7340–7358.
Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H
et al. (2000). Phosphorylation of Bcl-2 protein by CDC2 kinase
during G2/M phases and its role in cell cycle regulation. J Biol
Chem 275: 21661–21667.
Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in
cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:
48–58.
Hadfield JA, Ducki S, Hirst N, McGown AT (2003). Tubulin and
microtubules as targets for anticancer drugs. Prog Cell Cycle Res 5:
309–325.
Haldar S, Basu A, Croce CM (1997). Bcl2 is the guardian of
microtubule integrity. Cancer Res 57: 229–233.
Figure 4
Effects of MJ65–70 on the expression of cyclin B1, Cdk1 and JNK
protein in CH27 and M21 cells. The effect of MJ65–70 on the protein
levels of cyclin B1, Cdk1 and JNK were assessed by Western blot
analysis. Cells were incubated with 0.1% DMSO or IC50 concentra-
tions of MJ65–70 for 12 h. The concentrations of MJ72 used in CH27
and M21 are 10 and 8.1 μM respectively. Cell lysates were analysed
by SDS-PAGE (10% for cyclin B1; 12% for JNK and β-actin; 13% for
Bcl-2, pS70-Bcl-2 and Cdk1) and then probed with primary antibod-
ies as described . All results are representative of three independent
experiments.
BJPDevelopment of novel dual-targeted anti-cancer agents
British Journal of Pharmacology (2013) 169 1574–1586 1585
Hour MJ, Huang LJ, Kuo SC, Xia Y, Bastow K, Nakanishi Y et al.
(2000). 6-Alkylamino and 2,3-dihydro-3'-methoxy-2-phenyl-4-
quinazolinones and related compounds: their synthesis,
cytotoxicity and inhibition of tubulin polymerization. J Med Chem
43: 4479–4487.
Hour MJ, Lee KT, Wu YC, Wu CY, You BJ, Chen TL et al. (2013). A
novel antitubulin agent, DPQZ, induces cell apoptosis in human
oral cancer cells through Ras/Raf inhibition and MAP kinases
activation. Arch Toxicol 87: 835–846.
Kartalou M, Essigmann JM (2001). Mechanisms of resistance to
cisplatin. Mutat Res 478: 23–43.
Lee HZ, Yang WH, Hour MJ, Wu CY, Peng WH, Bao BY et al.
(2010). Photodynamic activity of aloe-emodin induces
resensitization of lung cancer cells to anoikis. Eur J Pharmacol 648:
50–58.
Ling YH, Tornos C, Perez-Soler R (1998). Phosphorylation of Bcl-2 is
a marker of M phase events and not a determinant of apoptosis.
J Biol Chem 273: 18984–18991.
Ma D, Warabi E, Yanagawa T, Kimura S, Harada H, Yamagata K et al.
(2009). Peroxiredoxin I plays a protective role against cisplatin
cytotoxicity through mitogen activated kinase signals. Oral Oncol
45: 1037–1043.
Manfredi JJ, Parness J, Horwitz SB (1982). Taxol binds to cellular
microtubules. J Cell Biol 94: 688–696.
Peters JM (2002). The anaphase-promoting complex: proteolysis in
mitosis and beyond. Mol Cell 9: 931–943.
Roninson IB, Broude EV, Chang BD (2001). If not apoptosis, then
what? Treatment-induced senescence and mitotic catastrophe in
tumor cells. Drug Resist Updat 4: 303–313.
Sánchez-Perez I, Murguía JR, Perona R (1998). Cisplatin induces a
persistent activation of JNK that is related to cell death. Oncogene
16: 533–540.
Wu YC, Hour MJ, Leung WC, Wu CY, Liu WZ, Chang YH et al.
(2011). 2-(Naphthalene-1-yl)-6-pyrrolidinyl-4-quinazolinone
inhibits skin cancer M21 cell proliferation through aberrant
expression of microtubules and the cell cycle. Pharmacol Exp Ther
338: 942–951.
Yang JS, Hour MJ, Kuo SC, Lee MR (2004). Selective induction of
G2/M arrest and apoptosis in HL-60 by a potent anticancer agent,
HMJ38. Anticancer Res 24: 1769–1778.
BJP M J Hour et al.
1586 British Journal of Pharmacology (2013) 169 1574–1586
